ideasIdea
A lifelong late-effects registry linked to every treatment for adult survivors
Children treated for cancer are followed for decades in a study that has changed how they are treated. Adults have nothing similar. Build it.
The Childhood Cancer Survivor Study transformed paediatric protocols by quantifying late cardiac, second-cancer and endocrine effects. Adult survivors, now over 18 million in the US alone, lack systematic long-term follow-up linked to treatment exposures, so late effects of immunotherapy, antibody-drug conjugates and modern radiotherapy are unknown. The proposal is a national registry linking treatment records, PROs and administrative outcomes for all adult survivors with consent, with open access for research.
Hypothesis
Within ten years the registry quantifies late effects for at least twenty modern regimens and leads to at least three changes in guideline dosing or surveillance.
Rationale
Late effects are invisible in trials that end at five years; only linked long-term data reveal them, and the paediatric precedent shows the payoff.
What would test it
Build in one country with existing registries (Nordic model) and demonstrate linkage completeness and first late-effect estimates within three years.
Maturity
early clinical
Who has to act
data
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
- Survivorship and late effects are neglected · Tens of millions of people live after cancer with heart damage, infertility, second cancers and fear, and few services.